Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ORIC
- Price
- 10.09
- Stock movement up
- +0.10 (1.00%)
- Company name
- Oric Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.13B
- Ent value
- 1.11B
- Price/Sales
- -
- Price/Book
- 2.94
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -15.18%
- 1 year return (CAGR)
- 22.01%
- 3 year return (CAGR)
- 24.65%
- 5 year return (CAGR)
- -21.90%
- 10 year return (CAGR)
- -
Last updated: 2026-03-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ORIC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 2.94 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 112.01M |
| EPS (TTM) | -1.47 |
| FCF per share (TTM) | -1.28 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -932.00K |
| Operating income (TTM) | -143.00M |
| Net income (TTM) | -129.47M |
| EPS (TTM) | -1.47 |
| EPS (1y forward) | -1.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 45.67M |
| Net receivables | 0.00 |
| Total current assets | 288.47M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 10.07M |
| Total assets | 411.00M |
| Accounts payable | 3.82M |
| Short/Current long term debt | 11.55M |
| Total current liabilities | 20.42M |
| Total liabilities | 26.64M |
| Shareholder's equity | 384.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -111.21M |
| Capital expenditures (TTM) | 872.00K |
| Free cash flow (TTM) | -112.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -33.68% |
| Return on Assets | -31.50% |
| Return on Invested Capital | -33.39% |
| Cash Return on Invested Capital | -28.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 10.00 |
| Daily high | 10.32 |
| Daily low | 9.94 |
| Daily Volume | 850K |
| All-time high | 39.80 |
| 1y analyst estimate | 21.23 |
| Beta | 1.36 |
| EPS (TTM) | -1.47 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 24 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ORIC | S&P500 | |
| Current price drop from All-time high | -74.65% | -1.82% |
| Highest price drop | -93.87% | -56.47% |
| Date of highest drop | 7 Nov 2022 | 9 Mar 2009 |
| Avg drop from high | -67.39% | -10.84% |
| Avg time to new high | 70 days | 12 days |
| Max time to new high | 1291 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.13B
Marketcap category
Small-cap
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Employees
104
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page